Arabic Arabic English English French French German German

Inspections and Use of Alternate Tools During the COVID-19 Public Health Emergency + Q/A Panel

Laurie Graham, Director for the Division of Internal Policies and Procedures, discusses site inspections, use of alternate tools, and the impact of travel restrictions during the COVID-19 Public Health Emergency (PHE).

This recording also includes a question and answer panel, also including Derek Smith, Deputy Director of the Office Pharmaceutical Manufacturing Assessment; CDER Tara Gooen Bizjak, Director of the Manufacturing Quality Guidance and Policy Staff; Alonza Cruse, Director of the Office of Pharmaceutical Quality Operations; and Neil Stiber, Associate Director of the Office of Quality Surveillance.

Panel discussion includes
Learn more at:
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training –
SBIA Listserv –
SBIA 2021 Playlist –
SBIA LinkedIn –
SBIA Training Resources –
Twitter –
Email –  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Risk Management and Application Approaches in Responding to Supply Chain Constraints During PHE

Next Post

Severe infections during pregnancy associated with complications around childbirth

Related Posts